Blood thinners after heart attack procedures showed more bleeding, with benefit uncertain
After a procedure to reopen a heart artery, anticoagulation—medicine that reduces clotting—was linked to more bleeding than placebo or no such treatment. Benefits for major cardiovascular outcomes remained statistically uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For patients with ST-elevation heart attacks treated by primary coronary intervention, pooled randomized trials found higher odds of bleeding with anticoagulation after the procedure. Death, major cardiovascular events, stent clots and stroke did not show statistically clear differences. These results do not prove the strategies are equivalent for those outcomes.
The abstract omits follow-up lengths, absolute event rates and the individual anticoagulant regimens, limiting interpretation of the pooled balance of benefits and harms.
What researchers found
Bleeding
Anticoagulation versus placebo/no anticoagulation after primary coronary intervention: bleeding odds ratio 1.78 (95% CI 1.07–2.97). Follow-up duration was not reported.
Understanding the bleeding estimate
An odds ratio compares event odds between groups, rather than giving a percentage increase in risk. The abstract does not report absolute bleeding rates, so it cannot show how many additional patients bled.
Uncertain cardiovascular differences
The confidence intervals for death and other cardiovascular outcomes included no difference. That means the trials did not establish a clear benefit or harm for those endpoints; it does not establish equivalence.
The original publication
Safety and efficacy of routine anticoagulation after primary PCI in STEMI: a systematic review and meta-analysis.
Chowdhury A, Vasoya DA, Ima MJ et al.
J Thromb Thrombolysis · 2025
- PubMed ID
- 40544386
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.